The Pharma Data

JUNE 7, 2023

Patients who experience metastases at distant sites typically have worse survival outcomes and a poor prognosis, thus these results showing a reduction in the risk of distant recurrence underscore the potential of neoantigen therapy,” said Kyle Holen, M.D., Moderna’s Senior Vice President and Head of Development, Therapeutics and Oncology.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

The Pharma Data

OCTOBER 25, 2021

Week 48 Data Met Safety and Efficacy Endpoints in Adults with HIV-1 Infection Currently on Antiretroviral Therapy. Merck Research Laboratories. “ Discontinue DELSTRIGO if estimated creatinine concurrence declines below 50 mL/ min. About Merck.

Treatment 52

Treatment Trials RNA Clinical Trials 52

The Pharma Data

OCTOBER 23, 2021

KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From the Phase 3 KEYNOTE-355 Study. Vicki Goodman, vice chairman, clinical exploration, Merck Research Laboratories. “

Treatment 52

Treatment Research Laboratories Trials Laboratories 52

The Pharma Data

JULY 21, 2021

mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. In the EU, VERQUVO (2.5 VERQUVO is being jointly developed by Merck and Bayer AG. mg, 5 mg and 10 mg). About Merck.

Treatment 52

Treatment Production Disease FDA Approval 52

The Pharma Data

NOVEMBER 18, 2021

50 copies/mL, demonstrating that antiviral efficacy was comparable between DOR/ISL and different antiretroviral therapy regimens (ILLUMINATE SWITCH A) and between DOR/ISL and bictegravir/emtricitabine/tenofovir (ILLUMINATE SWITCH B). About IMAGINE-DR. About Merck.

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

Codon

APRIL 2, 2023

A giant dataset about the rat brain, and how neurons connect to each other, was collected and pooled together from 20 different research laboratories. Read A one-time gene therapy injection for spinal muscular atrophy. mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 Gene Therapy.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

JULY 21, 2021

In the ongoing Phase 2a (NCT04003103) randomized, double-blind, parallel assignment, placebo-controlled, multicenter trial in adults at low-risk for acquiring HIV-1 infection, participants were randomly assigned (2:2:1) to one of three oral once-monthly therapy groups: islatravir 60 mg, islatravir 120 mg or placebo. About Merck.

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

NOVEMBER 9, 2020

Lilly’s chief scientific officer and president of Lilly Research Laboratories. “We’re proud of the speed with which we have been able to bring patients this therapy specifically designed to treat COVID-19. who require oxygen therapy due to COVID-19, OR. patients who recovered from COVID-19.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

JANUARY 20, 2021

“The approval of Verquvo provides doctors, health care professionals, and patients with a welcome new option to current available therapies.”. This approval builds upon Merck’s proud history of developing therapies for the treatment of patients with cardiovascular disease.”. Therapy was initiated at Verquvo 2.5

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

JUNE 7, 2022

Based on a post hoc analysis, fewer LAGEVRIO-treated participants in the MITT population required respiratory interventions (including conventional oxygen therapy, a high-flow heated and humidified device, noninvasive mechanical ventilation, or invasive mechanical ventilation) versus placebo-treated participants, with a RRR of 34.3% [95% CI, 4.3%

Hospitals 40

Hospitals Research Laboratories Treatment Disease 40

The Pharma Data

APRIL 16, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

Codon

JULY 21, 2024

As the biotechnologist Alex Telford writes , “Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments.” Although, given how salient the plight of research animals can be to the public and U.S.

Research 123

Research Engineering Disease Science 123

The Pharma Data

APRIL 7, 2023

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-003 and LEAP-017 investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai.

Trials 40

Trials Clinical Trials Treatment Therapies 40

The Pharma Data

MARCH 11, 2021

This new Phase 3 cohort of BLAZE-1 included 769 high-risk patients, aged 12 and older with mild to moderate COVID-19 (therapy: n=511; placebo: n=258). Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40

The Pharma Data

APRIL 4, 2023

Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. in these patients.

Treatment 40

Treatment FDA Approval FDA Therapies 40

Codon

JUNE 2, 2024

Without mouse models, we may never have developed polio and meningitis vaccines, organ transplants, GLP-1 drugs, gene therapies , or any other number of transformative treatments. Today, somewhere on the order of 30 million rodents are used yearly in biomedical research in the U.S.

Laboratories 127

Laboratories Research Disease Science 127